Medication-assisted treatment with methadone: Assessing the evidence

Psychiatric Services

Volumn 65, Issue 2, 2014, Pages 146-157

  Fullerton, Catherine Anne ^a   Kim, Meelee ^b   Thomas, Cindy Parks ^b   Lyman, D Russell ^c   Montejano, Leslie B ^a   Dougherty, Richard H ^c   Daniels, Allen S ^d   Ghose, Sushmita Shoma ^d   Delphin Rittmon, Miriam E ^e  

^a IBM WATSON HEALTH   (United States)

^b BRANDEIS UNIVERSITY   (United States)

^c DMA Health Strategies   (United States)

^d WESTAT   (United States)

^e SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PLACEBO; NARCOTIC ANALGESIC AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; CRIMINAL BEHAVIOR; DISEASE ASSOCIATION; DRUG EFFICACY; FETUS OUTCOME; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MEDLINE; MENTAL HEALTH SERVICE; META ANALYSIS; METHADONE TREATMENT; MORTALITY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PSYCHOSOCIAL CARE; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; FEMALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS;

ANALGESICS, OPIOID; FEMALE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84893688948     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300235     Document Type: Article

References (44)

1. Lloyd J: Drug Policy Information Clearinghouse Fact Sheet: Heroin. Washington, DC, Office of National Drug Control Policy, 2003
2. Results From the 2007 National Survey on Drug Use and Health: National Findings. NSDUH Series H-34, pub no SMA 08-4343. Rockville, Md, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2008
3. Goldstein A, Herrera J: Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug and Alcohol Dependence 40:139-150, 1995
4. Hulse GK, English DR, Milne E, et al: The quantification of mortality resulting from the regular use of illicit opiates. Addiction 94:221-229, 1999
5. Hser YI, Hoffman V, Grella CE, et al: A 33-year follow-up of narcotics addicts. Archives of General Psychiatry 58:503-508, 2001
6. Termorshuizen F, Krol A, Prins M, et al: Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. American Journal of Epidemiology 161:271-279, 2005
7. Thomas CP, Fullerton CA, Kim M, et al: Medication-assisted treatment with buprenorphine. Psychiatric Services, 2013; doi 10.1176/appi.ps.201300256
8. Galanter M, Kleber H (ed): The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th ed. Arlington, Va, American Psychiatric Publishing, 2008
9. D'Aunno T, Folz-Murphy N, Lin X: Changes in methadone treatment practices: results from a panel study, 1988-1995. American Journal of Drug and Alcohol Abuse 25:681-699, 1999
10. D'Aunno T, Pollack HA: Changes in methadone treatment practices: results from a national panel study, 1988-2000. JAMA 288:850-856, 2002
11. Dougherty RH, Lyman DR, George P, et al: Assessing the evidence base for behavioral health services: introduction to the series. Psychiatric Services, 2013; doi 10.1176/appi.ps.201300214
12. Sees KL, Delucchi KL, Masson C, et al: Methadone maintenance for opioid dependence. JAMA 284:694-695, 2000
13. Strain EC, Bigelow GE, Liebson IA, et al: Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281:1000-1005, 1999
14. Schwartz RP, Highfield DA, Jaffe JH, et al: A randomized controlled trial of interim methadone maintenance. Archives of General Psychiatry 63:102-109, 2006
15. Schwartz RP, Kelly SM, O'Grady KE, et al: Interim methadone treatment compared to standard methadone treatment: 4-month findings. Journal of Substance Abuse Treatment 41:21-29, 2011
16. Schwartz RP, Kelly SM, O'Grady KE, et al: Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction 107:943-952, 2012
17. Wilson ME, Schwartz RP, O'Grady KE, et al: Impact of interim methadone maintenance on HIV risk behaviors. Journal of Urban Health 87:586-591, 2010
18. Kandall SR, Doberczak TM, Jantunen M, et al: The methadone-maintained pregnancy. Clinics in Perinatology 26:173-183, 1999
19. McCarthy JJ, Leamon MH, Parr MS, et al: High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. American Journal of Obstetrics and Gynecology 193:606-610, 2005
20. Pizarro D, Habli M, Grier M, et al: Higher maternal doses of methadone does not increase neonatal abstinence syndrome. Journal of Substance Abuse Treatment 40: 295-298, 2011
21. Mattick RP, Breen C, Kimber J, et al: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 3:CD002209, 2009
22. Hall W, Ward J, Mattick R: The Effectiveness of Methadone Maintenance Treatment 1: Heroin Use and Crime. Amsterdam, Harwood Academic Publishers, 1998
23. Faggiano F, Vigna-Taglianti F, Versino E, et al: Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 3:CD002208, 2003
24. Fareed A, Casarella J, Amar R, et al: Methadone maintenance dosing guideline for opioid dependence, a literature review. Journal of Addictive Diseases 29:1-14, 2010
25. MacArthur GJ, Minozzi S, Martin N, et al: Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. British Medical Journal 345:e5945, 2012
26. Gowing L, Farrell MF, Bornemann R, et al: Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 8:CD004145, 2011
27. Fareed A, Vayalapalli S, Stout S, et al: Effect of methadone maintenance treatment on heroin craving, a literature review. Journal of Addictive Diseases 30: 27-38, 2011
28. Connock M, Juarez-Garcia A, Jowett S, et al: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment 11:1-171, iii-iv, 2007
29. Fletcher BW, Battjes RJ: Introduction to the special issue: treatment process in DATOS. Drug and Alcohol Dependence 57:81-87, 1999
30. Amato L, Minozzi S, Davoli M, et al: Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 10:CD004147, 2011
31. Cleary BJ, Donnelly J, Strawbridge J, et al: Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 105:2071-2084, 2010
32. Methadone-Associated Mortality: Report of a National Assessment, May 8-9, 2003. SAMHSA pub no 04-3904. Rockville, Md, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, 2004
33. Webster LR, Cochella S, Dasgupta N, et al: An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Medicine 12(Suppl 2): S26-S35, 2011
34. Martin JA, Campbell A, Killip T, et al; Substance Abuse and Mental Health Services Administration: QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. Journal of Addictive Diseases 30:283-306, 2011
35. Modesto-Lowe V, Brooks D, Petry N: Methadone deaths: risk factors in pain and addicted populations. Journal of General Internal Medicine 25:305-309, 2010
36. Jones HE, O'Grady KE, Malfi D, et al: Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. American Journal on Addictions 17:372-386, 2008
37. Kaltenbach K, Berghella V, Finnegan L: Opioid dependence during pregnancy. Effects and management. Obstetrics and Gynecology Clinics of North America 25: 139-151, 1998
38. Hulse GK, Milne E, English DR, et al: The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 92:1571-1579, 1997
39. Finnegan L, Kaltenbach K: Neonatal abstinence syndrome; in Primary Pediatric Care. Edited by Hoekelman RA, Friedman SB, Nelson NM, et al. St Louis, Mo, Mosby-Year Book, 1992
40. Ebner N, Rohrmeister K, Winklbaur B, et al: Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug and Alcohol Dependence 87:131-138, 2007
41. Dashe JS, Sheffield JS, Olscher DA, et al: Relationship between maternal methadone dosage and neonatal withdrawal. Obstetrics and Gynecology 100:1244-1249, 2002
42. American Academy of Pediatrics Committee on Drugs: Neonatal drug withdrawal. Pediatrics 101:1079-1088, 1998
43. Kaltenbach K, Finnegan LP: Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehavioral Toxicology and Teratology 6:271-275, 1984
44. Jones HE, Kaltenbach K, Heil SH, et al: Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine 363: 2320-2331, 2010 Services Administration Services Administration Services Administration